Complications Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark.
Novo Nordisk A/S, Søborg, Denmark.
Diabetes Obes Metab. 2019 May;21(5):1261-1265. doi: 10.1111/dom.13638. Epub 2019 Feb 22.
Liraglutide has pleiotropic effects favouring cardiovascular and renal risks. We investigated individual responses to liraglutide in six cardio-renal risk factors to examine whether responses in one risk factor are associated with changes in other risk factors (cross-dependency). We performed secondary analysis of the LIRA-RENAL trial (n = 279) in type 2 diabetes. HbA1c, body weight, systolic blood pressure (SBP) low density lipoprotein (LDL)-cholesterol, urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) were measured at baseline and after 26 weeks of liraglutide/placebo treatment: "Good responders" had a change within the best quartile. In the liraglutide-treated group, good HbA1c responders showed similar changes in other risk factors analysed to low responders (P ≥ 0.17). Good body weight responders had a larger reduction in HbA1c than low body weight responders (-1.6 ± 0.94 vs. -1.0 ± 0.82%; P = 0.003), but similar changes in the other risk factors (P ≥ 0.11). Good and low responders in SBP, UACR, LDL-cholesterol or eGFR showed similar changes in other risk factors (P ≥ 0.07). Treatment response to liraglutide is largely individual; aside from an association between body weight and HbA1c reduction, there are no obvious cross-dependencies in risk factor response.
利拉鲁肽具有有利于心血管和肾脏风险的多效作用。我们研究了利拉鲁肽在 6 个心肾风险因素中的个体反应，以检查一种风险因素的反应是否与其他风险因素的变化相关（交叉依赖性）。我们对 2 型糖尿病的 LIRA-RENAL 试验（n=279）进行了二次分析。在基线和利拉鲁肽/安慰剂治疗 26 周后测量了糖化血红蛋白（HbA1c）、体重、收缩压（SBP）、低密度脂蛋白（LDL）-胆固醇、尿白蛋白与肌酐比值（UACR）和估算肾小球滤过率（eGFR）：“良好反应者”的变化处于最佳四分位。在利拉鲁肽治疗组中，良好的 HbA1c 反应者与低反应者在分析的其他风险因素中表现出相似的变化（P≥0.17）。良好的体重反应者的 HbA1c 降低幅度大于低体重反应者（-1.6±0.94 与-1.0±0.82%；P=0.003），但其他风险因素的变化相似（P≥0.11）。SBP、UACR、LDL-胆固醇或 eGFR 的良好和低反应者在其他风险因素中的变化相似（P≥0.07）。利拉鲁肽的治疗反应在很大程度上是个体的；除了体重与 HbA1c 降低之间的关联外，风险因素反应没有明显的交叉依赖性。
